Welcome to our dedicated page for Context Therapeutics SEC filings (Ticker: CNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Context Therapeutics Inc. filings document a Nasdaq-listed clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies for solid tumors. Form 8-K reports include Regulation FD corporate presentations, operating and financial results, clinical-trial updates, and the FDA Fast Track designation for CTIM-76 in platinum-resistant ovarian cancer.
Proxy and governance filings describe annual meeting matters, director elections, stockholder voting procedures and common stock matters. Charter-related material-event reports document corrections to certificate provisions governing director terms and removal rights, along with associated Delaware court and stockholder-governance disclosures.
Context Therapeutics Inc. has amended its license agreement with BioAtla for CT-202, its Nectin-4 x CD3 T cell engaging bispecific antibody. The company will pay BioAtla $4.5 million within five business days of May 14, 2026 and another $2.0 million by August 1, 2026. In return, Context’s exclusive licenses to the CT-202 and related antibodies become irrevocable, royalty-free, fully paid-up and non-terminable, and BioAtla loses termination rights. BioAtla will no longer receive milestone payments or royalties on these antibodies, giving Context full economic upside as it plans to start a Phase 1 CT-202 trial in the third quarter of 2026.
Context Therapeutics Inc. ownership disclosure: Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl filed a joint Schedule 13G/A amendment reporting shared beneficial ownership of 2,238,496 shares of Context Therapeutics common stock, representing 2.44% of the class.
The filing states the percentage is calculated using 91,879,177 shares outstanding as of April 28, 2026 and shows shared voting and dispositive power over the reported shares. The Reporting Persons executed a Joint Filing Agreement dated May 15, 2026.
Context Therapeutics Inc. ownership update: Blue Owl Capital Holdings LP reports beneficial ownership of 5,089,015 shares of Common Stock, representing 5.54% of the class based on 91,879,177 shares outstanding as of May 4, 2026, per the issuer's 10-Q.
The filing is an amendment to a Schedule 13G/A and is signed by the Reporting Person's Chief Compliance Officer.
Context Therapeutics Inc. reports a Schedule 13G disclosure showing 5,250,000 shares of Common Stock beneficially owned, representing 5.7% of the class. The filing is a joint statement by Octagon Capital Advisors LP, Octagon Investments Master Fund LP and Ting Jia. The disclosed position is held with shared voting and shared dispositive power for 5,250,000 shares. The filing notes that Octagon is the investment advisor to the Master Fund and that Dr. Jia is Octagon's controlling member; the Master Fund holds the shares for its investors.
Context Therapeutics Inc. ownership update: an amendment to a Schedule 13G/A reports that Avidity-related entities and Michael Gregory hold sizeable shared voting and dispositive positions in the company. The disclosure lists 8,302,808 shares (representing 8.7%) for several Avidity entities and for Michael Gregory, and 7,364,795 shares (representing 7.7%) for Avidity Private Master Fund I.
The filing states these securities are directly owned by advisory clients of Avidity Partners Management LP and that the holdings are reported as shared voting and shared dispositive powers. Signatures and exhibits include a Joint Filing Agreement and Control Person identification; the filing is signed by Michael Gregory as managing member on 05/12/2026.
Soleus Capital Master Fund, L.P. and affiliated entities report shared voting and dispositive power over 6,963,141 shares of Context Therapeutics Inc. common stock, representing 7.6% of the class.
The percentage is calculated using 91,879,177 shares outstanding as of May 4, 2026 per the Issuer's Form 10-Q. The filing (Amendment No. 1 to Schedule 13G/A) lists the ownership chain and contains a standard disclaimer that certain affiliates and Guy Levy disclaim beneficial ownership except for Section 13(d) purposes.
Context Therapeutics Inc. reported a Q1 2026 net loss of $8.7 million, wider than the prior year, driven by higher research and development spending on its three T cell engaging antibody programs CTIM-76, CT-95 and CT-202. Research and development expenses reached $7.0 million, with growing clinical and manufacturing costs as CTIM-76 and CT-95 advance through Phase 1 trials and CT-202 moves toward first-in-human dosing. General and administrative costs were $2.3 million. The company ended March 31, 2026 with $54.5 million in cash and cash equivalents and an accumulated deficit of $139.6 million, and expects existing cash to fund operations into mid-2027 while it progresses early-stage clinical trials.
Context Therapeutics Inc. reports the resolution of a Delaware stockholder class action challenging parts of its charter. The Court of Chancery previously determined that charter provisions giving directors three-year terms and removal only for cause were invalid, and the company filed a Certificate of Correction to remove them.
Under a new letter agreement, a third-party service provider paid a $850,000 Mootness Fee to plaintiff’s counsel in full on the company’s behalf. The Court then granted an order closing the case, which will formally end after the Court is informed a quorum was achieved at the 2026 annual stockholders’ meeting scheduled for June 24, 2026.
Context Therapeutics Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 24, 2026 at 8:00 a.m. Eastern Time. Stockholders of record as of April 27, 2026, when 91,879,177 common shares were outstanding, may vote online or by proxy.
Investors are asked to elect seven directors for one-year terms, ratify CohnReznick LLP as independent auditor for 2026, and approve a charter amendment increasing authorized common stock from 200,000,000 to 300,000,000 shares to preserve flexibility for future financing, compensation and strategic uses. A separate proposal would allow adjournment of the meeting to solicit more proxies, particularly for the share increase, or to reach the 33 1/3% quorum required by Nasdaq rules.
The proxy statement also details board committee structures, independence determinations, risk oversight, insider trading and anti-hedging policies, and the background of directors and executive officers.